We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

On the winning side of Wall Street were Novo Nordisk’s U.S.-listed shares, which jumped 8.5%. The Danish company reported ...